

Investigator-Initiated Research: Areas of Interest

Updated May 2018

Vaccines

Qualified researchers are invited to submit investigator-initiated research (IIR) proposals, according to the guidance and instructions found on the Pfizer IIR portal at www.Pfizer.com/IIR. All proposals must be submitted via the IIR submission portal at: <https://iirsubmission.pfizer.com>. An IIR proposal requesting Pfizer support (e.g., funding and/or drug supply) is not a guarantee of acceptance or approval of that proposal. Decisions on support for IIR submissions are made by the applicable Pfizer Global Review Committee. A formal notification regarding the status of your application will be sent once a decision is reached. Pfizer support will only be extended upon the execution of an IIR agreement. For any questions, please send an email to IIR@pfizer.com.

Meningococcal disease

Research areas to be considered for Pfizer support include:

Epidemiology

- Invasive meningococcal disease (IMD)
 - Burden of invasive meningococcal disease in children and adults, including atypical presentation of IMD
 - Burden of invasive meningococcal disease in clinical condition or patient population (e.g. individuals at increased risk of meningococcal disease)
- Nasopharyngeal carriage in children and adults
 - Including epidemiological carriage studies in different populations (adolescents in general, students in halls of residence, military, mass gatherings)
- Characterization of meningococcal disease isolates from a region or country

Adult and adolescent immunization practices and uptake

- Research programs to examine barriers in adults and adolescents and evaluating impact of overcoming these barriers.

Impact of disease

- Includes impact on survivors and families/careers, both physical and psychological

Vaccine Effectiveness or Vaccine Impact

- Studies designed to ascertain vaccine effectiveness or impact of a vaccine program will be considered.

Pneumococcal disease

Research areas to be considered for Pfizer support include:

- Studies evaluating the burden of pneumococcal disease and serotype distribution in children and/or adults prior to, or following, the implementation of PCV13 immunization programs. In addition, surveillance is conducted following the implementation of PCV10 in order to establish the remaining Burden of Disease (BoD) and serotype distribution:
 - Invasive Pneumococcal Disease (IPD)
 - Pneumonia
 - Acute Otitis Media (AOM) (children)
- Nasopharyngeal carriage in children and/or adults prior to, or following, the implementation of PCV immunization programs
- Antibiotic resistant *S. pneumoniae* in children and/or adults prior to, or following, the implementation of PCV immunization programs
- Association of pneumococcal disease with influenza or other viral illnesses in children and/or adults

Tick-borne Encephalitis

Research areas to be considered for Pfizer support include:

Identification of new TBE-endemic areas, virus-epidemiology

- Tick surveillance, reservoir animals, human infection, human disease
- Molecular characterization of TBEV and “virulence genes”

Explore Burden of Disease:

- Characterization of the clinical course or the natural course after infection
- Diagnostics (e.g. adherence to guidelines, improvement of diagnostics, etc.)
- Disease and sequelae in children and adults

Vaccinology:

- Vaccine impact, effectiveness and cross neutralizing capacity
- Closing vaccination gaps

New vaccination targets:

- TBE in travelers (original clinical studies)
- TBE in other exposed subjects (i.e., children, elderly)
- Organisation of vaccination of travellers

Pfizer is not currently accepting proposals focusing on:

- Immune responses following immunization in any (sub-) group of patients or healthy subjects
- Seropersistence (studies available / ongoing)